Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Akorn, Inc.
The UK-based company is seeking to raise a further $100m in 2021 following the recent US clearance of its first product, a daytime-use neurostimulation device for snoring and mild obstructive sleep apnea.
As Apotex names its new US president and CEO, Akorn puts together a fresh board of directors following bankruptcy proceedings. Stada has made new appointments in Germany, while Siegfried makes significant changes in its leadership roles.
Akorn aims for “long-term growth and a brighter future” after exiting Chapter 11 protection that it had filed for in May 2020. After completing the sale to its lenders, the company is now operating as a private entity under the legal name, Akorn Operating Company LLC.
Just three years after Fresenius Kabi agreed a $4.75bn takeover of the US injectables specialist, Akorn has obtained approval from a US bankruptcy court for its sale to the company’s existing lenders, having filed for Chapter 11 bankruptcy earlier this year.
- Medical Devices
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
- Hi-Tech Pharmacal
- Oak Pharmaceuticals, Inc., VersaPharm